Abstract:Background The prevalence of inflammatory bowel disease (IBD) has been on the rise in developing countries. However, the mechanism of interaction between gut microbiota and immunity, especially how probiotics regulate the imbalance of mucosal immunity in IBD, remains unclear. Hence, this study aims to explore the role of Clostridium butyricum (C. butyricum) in M2 macrophage-mediated intestinal barrier injury repairation regarding the mechanism of efferocytosis. Methods C. butyricum was treated in DSS-induced colitis mice to observe the gut barrier and the macrophage phenotype (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (A) The flow chart of the experiment). The efferocytosis-related gene expression in terms of mucosal healing was explored in colitis mice with or without clodronate liposome treatment. RNA-sequencing was used to study the mechanism of C. butyricum on macrophage efferocytosis. Results We found that C. butyricum relieved intestinal inflammation and intestinal barrier injury in colitis mice (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (B,C) The wight loss and histological images of mice). M2 macrophages and the efferocytosis-related genes were upregulated after C. butyricum treatment (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (D-I) The frequency and efferocytosis-related genes expression of macrophage). Macrophage deletion induced by clodronate liposomes prevented the role of C. butyricum on the intestinal barrier and macrophage phenotype (IDDF2024-ABS-0252 Figure 1. C. butyricum promoted polarization and efferocytosis of macrophage in colitis mice (J-M) The effect of C. butyricum after macrophage clearance). RNA-sequencing revealed differentially expressed genes upregulated and downregulated (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (A) The numbers of differentially expressed genes after C. butyricum treatment). KEGG enrichment results suggested that the PPAR pathway were significantly enriched and the expression of PPAR pathway-related genes was identified (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (B,C) The result of enrichment analysis and differentially expressed genes that enriched in PPAR pathway). C. butyricum upregulated the expression of PPARδ and PPARγ, not PPARα (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (D-F) The relative expression of genes). Furthermore, PPARγ inhibitor GW9662 instead of PPARδ inhibitor GSK3787 could prevent the role of C. butyricum in inflammation suppression and macrophage efferocytosis promotion (IDDF2024-ABS-0252 Figure 2. The role of C. butyricum on inflammation suppression and efferocytosis was mediated PPAR╬│ activation (G,H) The weight loss and colon length of mice). Conclusions Our findings demonstrated that C. butyricum attenuated intestinal inflammation and barrier injury by promoting M2 macrophage polarization and efferocytosis, which is partly mediated by PPARγ activation.

Butyrate Ameliorated-Nlrc3 Protects the Intestinal Barrier in a GPR43-dependent Manner.

Butyrate Attenuates Intestinal Inflammation in Crohn’s Disease by Suppressing Pyroptosis of Intestinal Epithelial Cells Via the Cgsa-Sting-nlrp3 Axis

Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells’ Differentiation and Function in Induction of Colitis

Butyrate Inhibits the HDAC8/NF-κB Pathway to Enhance Slc26a3 Expression and Improve the Intestinal Epithelial Barrier to Relieve Colitis

Lactate Protects Intestinal Epithelial Barrier Function from Dextran Sulfate Sodium-Induced Damage by GPR81 Signaling

Butyrate Induces Intestinal Epithelial Cell to Express Thrombospondin 1 and Suppress Intestinal Mucosal Inflammation

Lactobacillus Alleviates Intestinal Epithelial Barrier Function Through GPR43-mediated M2 Macrophage Polarization

Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease

Butyrate Inhibits Interleukin-17 and Generates Tregs to Ameliorate Colorectal Colitis in Rats

Lactobacillus gasseri ATCC33323 affects the intestinal mucosal barrier to ameliorate DSS-induced colitis through the NR1I3-mediated regulation of E-cadherin

IDDF2024-ABS-0252 Clostridium Butyricum Attenuates Intestinal Barrier Injury by Promoting PPARγ-mediated Efferocytosis in Macrophages

Butyrate alleviates murine colitis by promoting the expansion of myeloid-derived suppressor cells

Butyrate Protects Barrier Integrity and Suppresses Immune Activation in a Caco-2/PBMC Co-Culture Model While HDAC Inhibition Mimics Butyrate in Restoring Cytokine-Induced Barrier Disruption

Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model

Butyrate Ameliorates Intestinal Epithelial Barrier Injury Via Enhancing Foxp3+ Regulatory T-Cell Function in Severe Acute Pancreatitis Model

Short-Chain Fatty Acids Manifest Stimulative and Protective Effects on Intestinal Barrier Function Through the Inhibition of NLRP3 Inflammasome and Autophagy

Butyrate Suppresses Abnormal Proliferation in Colonic Epithelial Cells under Diabetic State by Targeting HMGB1

Sodium Butyrate Attenuates Diarrhea in Weaned Piglets and Promotes Tight Junction Protein Expression in Colon in a GPR109A-Dependent Manner.

Gut microbiota-derived butyrate regulates gut mucus barrier repair by activating the macrophage/WNT/ERK signaling pathway.

Butyrate attenuates intestinal inflammation in Crohn's disease by suppressing pyroptosis of intestinal epithelial cells via the cGSA-STING-NLRP3 axis

Clostridium butyricum upregulates GPR109A/AMPK/PGC-1α and ameliorates acute pancreatitis-associated intestinal barrier injury in mice